Akums Drugs and Pharmaceuticals Limited (NSE:AKUMS)

Revenue by Segment

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
CDMO	37.10B	34.40B	36.20B	31.21B	29.78B
CDMO Growth	7.85%	-4.96%	15.99%	4.80%	24.04%
API	2.31B	2.77B	2.78B	2.22B	1.36B
API Growth	-16.50%	-0.47%	25.26%	63.33%	20151.19%
Domestic Branded Formulations	4.46B	4.34B	3.98B	-	-
Domestic Branded Formulations Growth	2.93%	8.81%	-	-	-
International Branded Formulations	1.43B	1.43B	1.25B	-	-
International Branded Formulations Growth	0.60%	14.26%	-	-	-
Inter-Segment	-2.73B	-2.93B	-4.20B	-4.43B	-3.45B
Trade Generics	1.00B	1.18B	1.77B	-	-
Trade Generics Growth	-14.89%	-33.27%	-	-	-
Branded and Generic Formulations	-	-	-	7.55B	9.03B
Branded and Generic Formulations Growth	-	-	-	-16.39%	54.21%
Total	43.59B	41.18B	41.78B	36.55B	36.72B
Total Growth	5.85%	-1.44%	14.32%	-0.46%	34.87%

Revenue by Geography

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
India	43.61B	41.21B	41.82B	36.57B	36.75B
India Growth	5.84%	-1.45%	14.34%	-0.49%	34.81%
Total	43.61B	41.21B	41.82B	36.57B	36.75B
Total Growth	5.84%	-1.45%	14.34%	-0.49%	34.81%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 10, 2026

Data Sources Report a data error